- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Trusopt ( Dorzolamide ophthalmic )
Trusopt (dorzolamide hydrochloride ophthalmic solution) 2% is a topical carbonic anhydrase inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with open‑angle glaucoma or ocular hypertension who are insufficiently responsive to beta‑blockers or in whom beta‑blockers are contraindicated. It works by inhibiting carbonic anhydrase in the ciliary processes of the eye, thereby decreasing the production of aqueous humour and lowering IOP. Trusopt may be used as monotherapy or in combination with other topical ophthalmic agents to achieve target IOP. It is not a miotic and does not cause accommodative spasm or night blindness.
Usual adult dose: The recommended dose is one drop of Trusopt 2% in the affected eye(s) three times daily. If more than one topical ophthalmic drug is being used, the medications should be instilled at least 5 minutes apart. To minimize systemic absorption and the risk of systemic side effects, patients should apply gentle pressure to the nasolacrimal sac (punctal occlusion) or gently close the eyelid for 1 to 2 minutes after instillation. If a dose is missed, it should be taken as soon as remembered, and the patient should then return to the regular schedule. The tip of the dispensing container must not touch the eye or surrounding structures to prevent contamination.
Dosage form: Sterile ophthalmic solution: 2% (each mL contains 20 mg of dorzolamide, equivalent to 22.26 mg of dorzolamide hydrochloride). Available in 5 mL and 10 mL dropper bottles. The product also contains benzalkonium chloride as a preservative; patients who wear soft contact lenses should remove them before instillation and wait at least 15 minutes before reinserting.
Onset of action: A reduction in intraocular pressure may be observed within 30 to 60 minutes of instillation, with peak IOP‑lowering effect occurring approximately 2 hours after dosing. Consistent three‑times‑daily administration is needed to maintain pressure control throughout the day.
Duration of action: The IOP‑lowering effect persists for approximately 8 to 12 hours, supporting a three‑times‑daily regimen. The plasma elimination half‑life of dorzolamide after topical ocular dosing is approximately 4 months due to slow release from red blood cells, but systemic concentrations are low and not correlated to ocular efficacy.
Alcohol recommendation: No direct interaction between topical dorzolamide and alcohol is known. However, excessive alcohol consumption may lead to systemic dehydration and transient fluctuations in blood pressure, which could theoretically affect ocular perfusion in patients with compromised optic nerve circulation. Moderation is advised.
Most common side effects: Ocular burning, stinging, and discomfort immediately after instillation (reported in up to one‑third of patients), bitter taste (dysgeusia), superficial punctate keratitis, transient blurred vision, tearing, and conjunctival hyperemia. These local effects are generally mild and resolve with continued use. Dorzolamide is a sulfonamide and, although applied topically, is absorbed systemically; therefore, the same types of adverse reactions attributable to sulfonamides may occur, including Stevens‑Johnson syndrome, toxic epidermal necrolysis, and aplastic anemia. Trusopt should be discontinued at the first sign of a serious skin or systemic hypersensitivity reaction. Caution is advised in patients with a history of renal calculi, severe renal impairment, or chronic corneal defects, including low endothelial cell counts. The concomitant use of oral carbonic anhydrase inhibitors and Trusopt is not recommended due to the risk of additive systemic effects. Patients should be monitored for any changes in vision, eye pain, or signs of corneal decompensation.
Would you like to try Trusopt (Dorzolamide ophthalmic) without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
